Biogennix commenced the launch of OsteoSPAN Fiber Matrix.
Comprising 100% demineralized cortical fibers, OsteoSPAN Fiber Matrix has been engineered for optimized handling while providing verified osteoinductive potential and an osteoconductive scaffold that supports cellular bone formation and stimulates fusion. OsteoSPAN Fiber Matrix is also processed to provide rapid, consistent hydration and fluid retention while resisting irrigation.
The OsteoSPAN Fiber Matrix is moldable and cohesive when hydrated with blood or bone marrow, and expands to conform irregular bone voids. The product is available in 1cc, 2.5cc, 5cc and 10cc volumes.
“OsteoSPAN Fiber Matrix is Biogennix’ first allograft product,” said Biogennix CTO Mark Borden. “We’re excited to expand our portfolio to include allografts, which will complement our comprehensive synthetic offering and allow us to access a new segment of the bone graft market.”
Biogennix commenced the launch of OsteoSPAN Fiber Matrix.
Comprising 100% demineralized cortical fibers, OsteoSPAN Fiber Matrix has been engineered for optimized handling while providing verified osteoinductive potential and an osteoconductive scaffold that supports cellular bone formation and stimulates fusion. OsteoSPAN Fiber Matrix is also...
Biogennix commenced the launch of OsteoSPAN Fiber Matrix.
Comprising 100% demineralized cortical fibers, OsteoSPAN Fiber Matrix has been engineered for optimized handling while providing verified osteoinductive potential and an osteoconductive scaffold that supports cellular bone formation and stimulates fusion. OsteoSPAN Fiber Matrix is also processed to provide rapid, consistent hydration and fluid retention while resisting irrigation.
The OsteoSPAN Fiber Matrix is moldable and cohesive when hydrated with blood or bone marrow, and expands to conform irregular bone voids. The product is available in 1cc, 2.5cc, 5cc and 10cc volumes.
“OsteoSPAN Fiber Matrix is Biogennix’ first allograft product,” said Biogennix CTO Mark Borden. “We’re excited to expand our portfolio to include allografts, which will complement our comprehensive synthetic offering and allow us to access a new segment of the bone graft market.”
Copy to clipboard 
